Sumitomo Pharma America Reveals Promising Clinical Data for SMP-3124LP at ASCO 2026
Sumitomo Pharma America, Inc. (SMPA) has presented clinical data from its first-in-human Phase 1/2 trial of SMP-3124LP, a selective checkpoint kinase 1 (CHK1) inhibitor, at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. The investigational drug, delivered via a PEGylated liposome formulation, is designed to treat malignancies with high replication stress. The trial enrolled 61 patients with advanced solid tumors, showing a 48.2% disease control rate and five partial responses. The drug was generally well-tolerated, with manageable safety profiles, and no dose-limiting toxicities were observed at lower doses. 
